Abstract: The present application discloses compositions and methods of synthesis and use involving click chemistry reactions for in vivo or in vitro formation of therapeutic and/or diagnostic complexes. Preferably, the diagnostic complex is of use for 18F imaging, while the therapeutic complex is of use for targeted delivery of chemotherapeutic drugs or toxins. More preferably, a chelating moiety or targetable construct may be conjugated to a targeting molecule, such as an antibody or antibody fragment, using a click chemistry reaction involving cyclooctyne, nitrone or azide reactive moieties. In most preferred embodiments, the click chemistry reaction occurs in vivo. In vivo click chemistry is not limited to 18F labeling but can be used for delivering a variety of therapeutic and/or diagnostic agents.
Type:
Grant
Filed:
January 29, 2013
Date of Patent:
July 30, 2013
Assignee:
Immunomedics, Inc.
Inventors:
William J. McBride, Christopher A. D'Souza, David M. Goldenberg
Abstract: Compositions and methods are disclosed for evaluating a subject's vasculature integrity, for differentiating between a malignant lesion and a benign lesion, for evaluating the accessibility of a tumor to nano-sized therapeutics, for treating tumors, and for live or real time monitoring of a nano-probe's biodistribution.
Type:
Application
Filed:
December 17, 2012
Publication date:
July 25, 2013
Inventors:
Ananth Annapragada, Ravi V. Bellamkonda, Efstathios Karathanasis, Russell M. Lebovitz
Abstract: The present invention provides targeted delivery compositions and methods of using the compositions for treating and diagnosing a disease state in a subject.
Abstract: A system for producing microbeads includes a microfluidic device defining a supply channel and a shearing channel, a microbead precursor material disposed in the supply channel, a carrier fluid disposed in the shearing channel, and a pressure distribution system fluidly connected to each of the supply channel and the shearing channel to control at least relative pressures of the microbead precursor material and the carrier fluid. The supply channel includes a check valve adapted to be subjected to a bias pressure that is sufficient to close the check valve to flow of microbead precursor material when a supply pressure of the microbead precursor material is below a threshold pressure and is open to flow of the microbead precursor material when the supply pressure of the microbead precursor material is greater than the threshold pressure.
Type:
Application
Filed:
October 3, 2011
Publication date:
July 18, 2013
Applicant:
The Johns Hopkins University
Inventors:
Tza-Huei Wang, Weijie Beh, Dara L. Kraitchman, Hsa-Quan Mao
Abstract: One embodiment of the disclosure provides an amino sequence of an anti-human transferrin receptor antibody, including: an amino sequence of a heavy chain variable region which is represented by SEQ ID NO.: 1 or SEQ ID NO.: 2, wherein the anti-human transferrin receptor antibody is capable of specifically binding to a human transferrin receptor.
Type:
Application
Filed:
September 11, 2012
Publication date:
July 4, 2013
Inventors:
Ming-Hua YANG, Min-Yuan Chou, Hsiang-Ching Wang
Abstract: A method for detecting antigen associated with adenocarcinoma commences by forming a 124I conjugate of a preferential locator, such as an antibody, and introducing the conjugate into a patient suspected of having adenocarcinoma. Positron emission tomography (PET) scanning of the patient reveals sites of accumulated conjugate, such sites including lymph nodes. The course of treatment of the patient then is determined by the amount of revealed lymph nodes.
Abstract: This invention relates to methods for evaluating the efficacy of an IGF1R inhibitor, such as an anti-IGF1R antibody, for the treatment of an Ewing's sarcoma tumor by determining the level of tumoral glucose metabolism. Tumoral glucose metabolism is determining at an early point in the treatment regimen by any of several methods known in the art including FDG-PET/CT scan.
Type:
Grant
Filed:
September 10, 2010
Date of Patent:
June 25, 2013
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Brian DerHua Lu, Siu-Long Yao, Cynthia Seidel-Dugan, Yan Wang
Abstract: A system automatically processes different medical image sequences facilitating comparison of the sequences in adjacent respective display areas. An image data processor, identifies first and second mask images of first and second image sequences respectively as images preceding introduction of contrast agent and determines a translational shift between the first and second mask images. The image data processor transforms data representing individual images of at least one of the first image sequence and the second image sequence in response to the determined translational shift to reduce mis-alignment of the individual images of the first image sequence relative to the individual images of the second image sequence. A display presents first and second image sequences corrected for mis-alignment, in substantially adjacent display areas to facilitate user comparison.
Abstract: Metal chelators of Formula I and Formula II are disclosed: or a pharmaceutically acceptable salt thereof. Also disclosed are metal chelator-targeting moiety complexes, metal chelator-targeting moiety-metal conjugates, kits, and methods of their preparation and use in diagnosis and/or treatment of diseases and conditions, including, inter alia, cancer and thrombosis.
Type:
Grant
Filed:
April 1, 2010
Date of Patent:
June 4, 2013
Assignee:
The United States of America, as represented by the Secretary, Department of Health And Human Services
Abstract: The present disclosure provides an isolated or recombinant IL-23-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain specifically binds to IL-23 but does not significantly bind to an IL-12p40 subunit and does not significantly bind to an IL-23p19 subunit when they are not components of IL-23. The present disclosure also provides uses of the IL-23-binding protein.
Type:
Application
Filed:
July 20, 2011
Publication date:
May 9, 2013
Applicant:
CEPHALON AUSTRALIA PTY LTD.
Inventors:
Adam William Clarke, Anthony G. Doyle, Matthew Pollard, Stephen Tran
Abstract: The invention provides SPARC binding antibodies that target disease sites, in particular, tumors and uses thereof to diagnose and treat diseases, in particular, cancerous tumors.
Abstract: Alkyl cyanoacrylate compositions and methods for making those compositions, utilizing high purity monomeric starting materials, formed into more viscous oligomers, and combined with a plasticizer and inhibitor to provide a single-container, storage stable medical cyanoacrylate.
Type:
Application
Filed:
July 9, 2012
Publication date:
April 11, 2013
Applicant:
Valor Medical, Inc.
Inventors:
Charles W. Kerber, H. Clark Adams, Peter Friedman
Abstract: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The cargo compound may be a nucleic acid and specifically a DNA, RNA or anti-sense. The invention further discloses methods for treating cancer and diagnosing cancer.
Type:
Application
Filed:
July 30, 2012
Publication date:
April 4, 2013
Applicant:
The Board of Trustees of the University of Illinois
Inventors:
Tapas Das Gupta, Ananda Chakrabarty, Craig Beattie, Tohru Yamada
Abstract: Imaging agents are described that comprise labeled substrates capable of being introduced into cells via the cystine/glutamate antiporter. The substrates may be used for imaging or detecting oxidative stress in cells by introducing the labeled agents into cells via the cystine/glutamate antiporter and subsequent detection.
Type:
Application
Filed:
September 16, 2011
Publication date:
March 21, 2013
Applicant:
GENERAL ELECTRIC COMPANY
Inventors:
Jack Mathew Webster, Bruce Fletcher Johnson, Brian Duh-Lan Lee, Chittari Pabba, Michael James Rishel
Abstract: The present invention provides modified stem cells that comprise a delivery system that comprises at least one microparticle or nanoparticle, wherein the at least one microparticle or nanoparticle comprises an active agent. The present invention also provides delivery methods that comprise the administration of the modified stem cells to a subject. Additional aspects of the present invention pertain to methods of making said modified stem cells.
Type:
Application
Filed:
March 17, 2011
Publication date:
March 21, 2013
Applicant:
Board of Regents of the University of Texas System
Inventors:
Jonathan O. Martinez, Ennio Tasciotti, Mikhail Kolonin, Mauro Ferrari
Abstract: Embodiments disclosed herein relate to improved X-ray contrast media compositions and methods of using the same for treating symptoms related to allergic reactions, inflammatory conditions, symptoms of the common cold and certain cancers.
Abstract: A biopsy marker having radio-opaque properties that are derived in situ, based on a natural a biological response, such as for example, calcification, accumulation or tissue-concentration of a chemical agent so as to provide an imaging contrast. A biodegradable foam such as collagen foam or gelatin foam is embedded with a biological tissue that is susceptible to the calcification. Initially the marker can be imaged using ultrasound, but over time, the embedded material calcifies causing it to become visible under radiation imaging.
Type:
Grant
Filed:
December 17, 2007
Date of Patent:
March 19, 2013
Assignee:
C. R. Bard, Inc.
Inventors:
Dnyanesh A. Talpade, Chandrashekhar Pathak
Abstract: An emulsion includes a substantially continuous liquid medium, and a plurality of droplet structures dispersed within the substantially continuous liquid medium. Each droplet structure of the plurality of droplet structures includes an outer droplet of a first liquid having an outer surface; an inner droplet of a second liquid within the first droplet, the second liquid being immiscible in the first liquid, wherein the inner and outer droplets have a boundary surface region therebetween; an outer layer of block copolymers disposed on the outer surface of the outer droplet; and an inner layer of block copolymers disposed on the boundary surface region between the outer and the inner droplets.
Type:
Application
Filed:
September 5, 2012
Publication date:
March 14, 2013
Applicant:
The Regents of the University of California
Inventors:
Thomas G. Mason, Timothy J. Deming, Jarrod A. Hanson, Connie B. Chang, Sara M. Graves
Abstract: A medical device has a structure made of a first biodegradable and/or bioabsorbable material and a second biodegradable and/or bioabsorbable material. The first biodegradable and/or bioabsorbable material has a degradation rate that is faster than a degradation rate of the second biodegradable and/or bioabsorbable material. And, the structure experiences a period of accelerated degradation upon exposure of the first biodegradable and/or bioabsorbable material.
Abstract: The invention encompasses radiopharmaceutical compounds that can be used in imaging cell death associated with either apoptosis or necrosis. Phosphatidylethanolamine (PtdE) is externalized to the surface of apoptotic cells, and also becomes accessible in necrotic cells due to compromised plasma membrane integrity. Duramycin, a 19 amino acid polypeptide, binds PtdE at a 1:1 ratio with high affinity and exclusive specificity. Novel Duramycin-based radiopharmaceuticals and non-radioactively labeled compounds are disclosed herein. Such compounds facilitate detection of cell apoptosis and/or necrosis by binding to PtdE. The location of the bound compound can then be pinpointed using standard imaging techniques.
Abstract: The invention relates to nanocrystals, containing one or more metals as defined in the specification; having a size of 2 to 200 nm; having a defined, three-dimensional polyhedral structure, optionally functionalized by ligands and/or embedded crystals. The invention further relates to monodisperse assemblies of such nanocrystals, to formulations and devices comprising such nanocrystals as well as to the manufacture and use thereof.
Type:
Application
Filed:
May 11, 2011
Publication date:
March 7, 2013
Applicant:
ETH ZURICH
Inventors:
Christophe Jan Lacroix, Christophe Chassard, Marcus Yaffee
Abstract: The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject.
Type:
Application
Filed:
August 3, 2012
Publication date:
March 7, 2013
Applicant:
BIOASIS TECHNOLOGIES, INC.
Inventors:
Wilfred Jefferies, Mei Mei Tian, Timothy Vitalis
Abstract: A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. In some embodiments, the method includes the steps of (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor one or more molecules of the library of diverse molecules, whereby a molecule that binds an irradiated tumor is identified. Also provided are targeting ligands that bind an irradiated tumor and therapeutic and diagnostic methods that employ the disclosed targeting ligands.
Type:
Grant
Filed:
February 1, 2011
Date of Patent:
March 5, 2013
Assignee:
Vanderbilt University
Inventors:
Dennis E. Hallahan, Shimian Qu, Zhaozhong Han
Abstract: Particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy)phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles can also include a core having a hydrogel formed from an acrylic-based polymer. Barium sulfate may also be provided to the core of the particles as a coating or absorbed within the core of the particles. The particles can be used to minimize blood flow to mammalian tissues by occluding at least a portion of a blood vessel of the mammal, or to deliver an active agent to a localized area within a body of a mammal by contacting a localized area with at least one of the particles. Further, the particles are useful in sustained release formulations including active agent(s) for oral administration, as tracer particles for injection into the bloodstream of a mammal or for use in enhanced ultrasound imaging.
Abstract: A contrast agent for angiography is disclosed, in particular, for examining animal or human bodies or components thereof such as members or organs thereof, comprising an essentially oil-based apolar contrast component for X-ray examinations, the contrast component having a contrast component viscosity in the range of 30-100 mPas. The contrast agent is characterised in that the contrast component is present in a mixture with at least one further apolar component, the viscosity of which is less than or at most equal to the contrast component viscosity. Methods for angiography examination are also disclosed, in which such a contrast agent or also a polar contrast agent are used at least periodically and applications of such contrast agents.
Abstract: A new approach to targeting imaging agents to macrophage-rich sites of interest is disclosed. Compositions of the invention are rHDL and HDL-like liposomal compositions, protein constituents of which, apolipoproteins A-I and/or A-II or fragments thereof are used not only as structural but also as targeting agents. This is achieved by certain controlled chemical or enzymatic modification of apolipoproteins A-I or A-II or fragments thereof. Such modification converts these apolipoproteins to substrates for macrophage scavenger receptors and results in the improvement of contrast agent-(HDL/modified apolipoprotein)-particle association with macrophages and/or absorption (uptake) by macrophages when compared to that of the contrast agent-(HDL/apolipoprotein)-particle constructed with non-modified naturally occurring apo A-I.
Abstract: The present invention teaches a micro-porous injectable, soft elastic, fully resorbable fibrin-based composition for use as a soft tissue lumen and void filler. The composition of the present application exhibits physical characteristics, such as mechanical properties, typically seen in elastomers and mechanical stability, which is superior to fibrin alone. A variety of properties of the composition of the present invention can be effectively fine-tuned and altered by adjusting type and content of the particles as well as of the plasticizer contained in the void filler composition.
Type:
Grant
Filed:
January 11, 2011
Date of Patent:
February 19, 2013
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Inventors:
John J. Barry, Andreas Goessl, Heinz Gulle, Monika Mangold, Melitta Bilban
Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as polyethylene glycol) (PEG) The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo The nanoparticle may further be conjugated to a ligand capable of binding to a cellular component associated with the specific cell type, such as a tumor marker A therapeutic agent may be attached to the nanoparticle Radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle to permit the nanoparticle to be detectable by various imaging techniques.
Type:
Application
Filed:
July 2, 2010
Publication date:
February 14, 2013
Applicants:
CORNELL UNIVERSITY, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
Inventors:
Michelle Bradbury, Ulrich Wiesner, Oula Penate Medina, Hoosweng Ow, Andrew Burns, Jason Lewis, Steven Larson
Abstract: Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.
Type:
Application
Filed:
July 31, 2012
Publication date:
February 14, 2013
Inventors:
David J. Yang, Dongfang Yu, Andrew S. Thompson, F. David Rollo
Abstract: A contrast agent for angiography is disclosed, in particular, for examining animal or human bodies or components thereof such as members or organs thereof, comprising an essentially oil-based apolar contrast component for X-ray examinations, the contrast component having a contrast component viscosity in the range of 30-100 mPas. The contrast agent is characterised in that the contrast component is present in a mixture with at least one further apolar component, the viscosity of which is less than or at most equal to the contrast component viscosity. Methods for angiography examination are also disclosed, in which such a contrast agent or also a polar contrast agent are used at least periodically and applications of such contrast agents.
Abstract: The present invention discloses Near Infrared (NIR) fluorescent albumin nanoparticles having a structure selected from a core structure or a core-shell structure. Also disclosed are a process of preparing these NIR fluorescent albumin nanoparticles, and a method of in vivo detection of pathologies, in particular cancer pathology, by using administering these NIR fluorescent albumin nanoparticles to a patient.
Type:
Application
Filed:
July 17, 2012
Publication date:
January 31, 2013
Applicant:
BAR ILAN UNIVERSITY
Inventors:
Shlomo Margel, Sarit Cohen, Enav Corem Salkmon, Michal Pellach
Abstract: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.
Abstract: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.
Type:
Grant
Filed:
January 8, 2009
Date of Patent:
January 29, 2013
Assignee:
Lantheus Medical Imaging, Inc.
Inventors:
Richard R. Cesati, Thomas D. Harris, Simon P. Robinson, Richard J. Looby, Edward H. Cheesman, Padmaja Yalamanchili, David S. Casebier
Abstract: A temporary embolic material for blood vessel which can embolize a blood vessel in a living body and is used for the temporary embolization of the blood stream. More specifically, disclosed is an embolus-forming material comprising a specific PVA particle which can be used for the closure of the inner lumen of a blood vessel by the PVA particle to embolize the blood stream, which can ultimately be absorbed in the living body, which can be excreted out of the body and which does not remain in the body. A pearl-like polyvinyl alcohol particle for use as a temporary embolic material, the particle having a saponification degree of 90 mol % or higher and an average particle diameter of 70 to 1000 ?m; and a temporary embolic material comprising the particle mixed or dissolved therein.
Type:
Grant
Filed:
June 28, 2006
Date of Patent:
January 29, 2013
Assignee:
The Nippon Synthetic Chemical Industry Co., Ltd.
Abstract: Compositions and methods are disclosed for evaluating a subject's vasculature integrity, for differentiating between a malignant lesion and a benign lesion, for evaluating the accessibility of a tumor to nano-sized therapeutics, for treating tumors, and for live or real time monitoring of a nano-probe's biodistribution.
Type:
Grant
Filed:
January 22, 2009
Date of Patent:
January 22, 2013
Inventors:
Ananth Annapragada, Efstathios Karathanasis, Ravi V. Bellamkonda, Russell M. Lebovitz
Abstract: The present invention provides a unit dosage of Apadenoson, a pharmacological stress agent, and use of the same as a pharmacologic agent for myocardial perfusion imaging.
Type:
Application
Filed:
July 9, 2012
Publication date:
January 17, 2013
Applicant:
University of Virginia Patent Foundation
Inventors:
Robert Hendel, William B. Stilley, Shannon P. Williams
Abstract: Agents and methods for imaging a cell and/or a portion of tissue characterized by fibrosis, as well as to agents and methods for determining and/or diagnosing fibrotic diseases are disclosed herein. Also disclosed herein are polymer conjugates that can include a detectable label, a retinoid and a polymer. The polymer conjugates can be used to image a portion of tissue, deliver a detectable label to a portion of tissue or a cell and/or diagnosis a condition or disease.
Type:
Application
Filed:
September 11, 2009
Publication date:
January 10, 2013
Applicant:
NITTO DENKO CORPORATION
Inventors:
Yoshiro Niitsu, Lei Yu, Gang Zhao, Sang Van, Xinghe Wang, Jian Liu, Sanjib Kumar Das, Yasunobu Tanaka, Keiko Kajiwara, Hirokazu Takahashi, Miyono Miyazaki
Abstract: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer.
Type:
Application
Filed:
June 25, 2012
Publication date:
January 10, 2013
Applicant:
The Board of Trustees of the University of Illinois
Inventors:
Ananda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Arsenio Fialho
Abstract: Disclosed are monoclonal antibodies that specifically bind to the B7 family member B7H6, including antibodies capable of inhibiting the interaction of B7H6 with NKp30. Also disclosed are anti-B7H6 antibody-drug conjugates comprising an anti-B7H6 monoclonal antibody conjugated to a therapeutic agent. The anti-B7H6 antibodies and antibody-drug conjugates are useful in methods for exerting therapeutic effects against B7H6-expressing cells, as well as in diagnostic methods for the detection of B7H6 or B7H6-expressing cells.
Type:
Application
Filed:
December 8, 2010
Publication date:
January 3, 2013
Inventors:
Michel Pierres, Eric Vivier, Myriam Baratin
Abstract: The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from Neisseria outer membrane proteins, such as Laz. The invention also provides synthetic transit peptides comprised of the pentapeptide AAEAP. The invention further discloses methods for treating cancer, and specifically brain cancer, as well as other brain-related conditions. Further, the invention provides methods of imaging and diagnosing cancer, particular brain cancer.
Type:
Application
Filed:
May 25, 2012
Publication date:
January 3, 2013
Applicant:
The Board of Trustees of the University of Illinois
Inventors:
Chang Soo Hong, Tohru Yamada, Arsenio M. Fialho, Tapas K. Das Gupta, Ananda M. Chakrabarty
Abstract: The invention relates to a process for the preparation of a diagnostic X-ray composition. The composition comprises a non-ionic X-ray contrast agent in a pharmaceutically acceptable carrier. More particularly, the invention relates to a process for secondary production of X-ray compositions comprising X-ray contrast agents with a high dissolution temperature. When using the process of the invention, precipitation is avoided and degradation of the contrast agent is reduced. The process of the invention includes heat treatment of iodinated X-ray contrast agents at low pH.
Abstract: This invention relates to diazabicyclononyl oxadiazolyl derivatives, which are found to-be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. Ar1 represents a pyrrolyl group, optionally substituted with alkyl or halo-alkyl.
Type:
Application
Filed:
December 16, 2010
Publication date:
January 3, 2013
Applicant:
NEUROSEARCH A/S
Inventors:
Dan Peters, Daniel B. Timmermann, Elsebet Østergaard Nielsen, Tino Dyhring, Philip K. Ahring
Abstract: Activity-based probes, which are specific for certain active cysteine proteases (caspase, cathepsin and legumain) and carry radioactive labels, are disclosed. The present probes comprise an acyloxymethyketone (AOMK) “warhead” that binds only to active enzyme. The probes further comprise peptide-like structure that targets the probe to a specific cysteine protease or protease family, and a radiolabel on the probe, which is bound to the targeted enzyme. It has been found that the present probes are stable in vivo and give specific target images distinguishable over background. The preferred probes are labeled with a positron-emitting agent such as 64Cu, 125I (SPECT) and 99mTc (PET). The probes show in vivo half-life and stability well suited for imaging.
Type:
Grant
Filed:
April 3, 2009
Date of Patent:
January 1, 2013
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Matthew S. Bogyo, Galia Blum, Alicia Berger, Zhen Cheng, Sanjiv S. Gambhir
Abstract: The present invention relates to formulations for use in medical or diagnostic procedures comprising a stabilizing agent alone or in combination with an osmotic agent. In one embodiment, the stabilizing agent is a natural hydrocolloid, preferably locust bean gum, and the osmotic agent is a sugar-based compound, preferably mannitol. The present invention also relates to formulations and methods for distending an anatomic segment. The present invention further relates to formulations and methods for delineating an anatomic segment on a diagnostic image, for example. The formulations of the present invention are especially suitable for use with diagnostic imaging procedures including, but not limited to, magnetic resonance imaging (MR), computer assisted tomography (CT), and CT-PET (position emission tomography), as well as other medical and therapeutic uses.
Type:
Grant
Filed:
September 19, 2008
Date of Patent:
January 1, 2013
Assignee:
Bracco Diagnostics Inc.
Inventors:
Thomas C. Lauenstein, Jorg F. Debatin, Hubert Schneemann
Abstract: [PROBLEM] To provide a monoclonal antibody against a biomarker which shows high specificity and can be effectively used in detection and diagnosis of various lesions relevant to various kinds of carcinomas and foci of necrosis, and so forth. [MEANS] A monoclonal antibody against a necrosis marker consisting the following amino acid sequence: (1) the amino acid sequence of SEQ ID NO: 1, or (2) an amino acid sequence having substitution, deletion and/or insertion of one or several amino acid residues in the amino acid sequence of (1) or sharing a homology of 90% or more with the amino acid sequence of (1), and showing the same function, activity or property as that of the amino acid sequence of (1) as a protein.
Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
Type:
Grant
Filed:
July 17, 2012
Date of Patent:
July 2, 2013
Assignee:
The Trustees Of The University Of Pennsylvania
Inventors:
Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang, Virginia M. Y. Lee, John Q. Trojanowski, Daniel M. Skovronsky
Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form-amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
Type:
Grant
Filed:
July 17, 2012
Date of Patent:
July 9, 2013
Assignee:
The Trustees Of The University Of Pennsylvania
Inventors:
Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang, Virginia M. Y. Lee, John Q. Trojanowski, Daniel M. Skovronsky